HC Wainwright Brokers Increase Earnings Estimates for ESPR

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Equities researchers at HC Wainwright raised their FY2025 earnings per share estimates for Esperion Therapeutics in a note issued to investors on Thursday, November 7th. HC Wainwright analyst J. Pantginis now expects that the biopharmaceutical company will earn $1.36 per share for the year, up from their previous forecast of $1.29. HC Wainwright has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.09) per share. HC Wainwright also issued estimates for Esperion Therapeutics’ FY2026 earnings at $2.25 EPS, FY2027 earnings at $3.14 EPS and FY2028 earnings at $6.05 EPS.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings data on Monday, August 12th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.10. The company had revenue of $73.83 million during the quarter, compared to the consensus estimate of $51.90 million.

A number of other equities analysts have also weighed in on the company. StockNews.com upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday. Needham & Company LLC dropped their target price on Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, August 13th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $8.17.

Esperion Therapeutics Stock Up 8.1 %

Esperion Therapeutics stock opened at $2.28 on Monday. The company’s 50-day moving average price is $1.91 and its two-hundred day moving average price is $2.13. The stock has a market cap of $447.39 million, a P/E ratio of -3.56 and a beta of 0.96. Esperion Therapeutics has a twelve month low of $0.87 and a twelve month high of $3.40.

Hedge Funds Weigh In On Esperion Therapeutics

A number of hedge funds have recently added to or reduced their stakes in ESPR. Intech Investment Management LLC bought a new position in shares of Esperion Therapeutics in the third quarter worth $94,000. Connor Clark & Lunn Investment Management Ltd. increased its stake in Esperion Therapeutics by 71.0% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 711,278 shares of the biopharmaceutical company’s stock valued at $1,174,000 after acquiring an additional 295,378 shares during the last quarter. Summit Wealth Group LLC acquired a new position in Esperion Therapeutics during the third quarter valued at approximately $66,000. Versor Investments LP bought a new stake in Esperion Therapeutics during the third quarter worth $44,000. Finally, Traphagen Investment Advisors LLC acquired a new stake in shares of Esperion Therapeutics in the 3rd quarter valued at $27,000. Institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.